Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: NATRECOR

Summary for Tradename: NATRECOR

Suppliers: see list1
patent expirations by year for

Pharmacology for Tradename: NATRECOR

Clinical Trials for: NATRECOR

Natrecor for Pulmonary Hypertension in Lung Transplants
Status: Completed Condition: Pulmonary Hypertension

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Status: Completed Condition: Congestive Heart Failure

Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Status: Terminated Condition: Congestive Heart Failure; Cardiac Transplantation; Renal Insufficiency; Renal Failure

A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
Status: Completed Condition: Cardiomyopathies; Heart Failure, Congestive; Dyspnea, Paroxysma

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status: Withdrawn Condition: Heart Failure, Congestive; Dyspnea; Pulmonary Edema

Natrecor in Pulmonary Hypertension
Status: Terminated Condition: Pulmonary Hypertension; Cancer; Lung Disease; Cardiothoracic Surgery

Nesiritide and Vo2 Max in Heart Failure Patients
Status: Completed Condition: Heart Failure

FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
Status: Completed Condition: Heart Failure, Congestive

Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Status: Terminated Condition: Heart Failure; Cardiovascular Disease; Acute Heart Failure; Diastolic Heart Failure; Congestive Heart Failure; Heart Disease

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
Status: Terminated Condition: Heart Defects, Congenital

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920Aug 10, 2001RXYes5,114,923<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology